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Inflammatory Bowel Disease as a Risk Factor for Premature
Coronary Artery Disease
Phillip Ruisia, e, John N. Makaryusb, Michael Ruisic, Amgad N. Makaryusd

Abstract
Background: Crohn’s disease and ulcerative colitis are both systemic
chronic diseases that alter bowel physiology. The central process in
inflammatory bowel disease (IBD) and the associated manifestations
are the result of B-cell production of IgG autoantibodies directed
against self-antigens in various organ systems including coronary
endothelium. Previous studies have demonstrated significant microvascular endothelial dysfunction in patients with IBD compared to
patients not affected by the disease. We sought to analyze the relation,
if any, between IBD and the development of premature coronary artery disease (CAD).
Methods: We queried our hospital database to find IBD patients admitted to the hospital from January 1, 2007 to December 31, 2008.
Patients with traditional cardiovascular (CV) disease risk factors including hypertension, congestive heart failure (CHF), diabetes, age ≥
65, hyperlipidemia, family history, end-stage renal disease (ESRD),
and greater than five pack-year smoking history were excluded from
the study cohort. The charts of the remaining 300 patients with diagnosed IBD were then analyzed for the incidence of CV disease events
including acute myocardial infarction (MI), unstable angina, positive
stress testing, and any cardiac intervention including coronary angioplasty and/or intracoronary stent implantation.
Results: Of the 300 patients included, only one patient had a CV
disease event. This patient had a positive exercise stress thallium test.
Otherwise, the remaining 299 patients (99.7%) did not have any reported CV disease events over the 2-year follow-up period.
Conclusion: Most of the clinical sequelae of CV disease events are
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the result of inflammatory changes at the vascular level. While IBD is
associated with a chronic inflammatory state as reflected by high sedimentation rates, C-reactive protein (CRP), homocysteine levels, etc.,
our data seem to indicate that chronic inflammation in the absence
of traditional risk factors is not associated with an increased risk of
premature CV disease events. More wide-scale prospective studies
should be performed to elucidate the relationship, if any, between
chronic inflammation and CV disease risk.
Keywords: Inflammatory bowel disease; Coronary artery disease;
Crohn’s disease; Ulcerative colitis

Introduction
The term “inflammatory bowel disease (IBD)” refers to two
primary diagnoses: Crohn’s disease and ulcerative colitis. Both
conditions are chronic inflammatory disease states associated
with a relapsing and remitting course with respect to disease
activity and symptomatology. The hallmark of both is a state
of chronic inflammation involving mainly the gastrointestinal
system with the potential for diffuse systemic involvement. In
North America, incidence rates range from 2.2 to 19.2 cases
per 100,000 person-years for ulcerative colitis and 3.1 to 20.2
cases per 100,000 person-years for Crohn’s disease. While the
incidence of ulcerative colitis has largely remained the same
over the last 100 years, the incidence of Crohn’s disease continues to rise [1, 2].
Given the chronic inflammatory state of both diseases as
evidenced on laboratory studies by elevated serum levels of
inflammatory markers such as C-reactive protein (CRP) and
homocysteine, along with well-known extra-intestinal inflammatory manifestations, one may postulate the association
of IBD with coronary inflammation and subsequent plaque
rupture and/or erosion leading to acute coronary syndromes
(ACS). Some of the extra-intestinal inflammatory conditions
such as migratory arthritis, anterior uveitis, erythema nodosum, pyoderma gangrenosum, and others have a clear documented inflammatory infiltrative process on pathology. In addition, Crohn’s disease is associated with the development of
calcium oxalate stones due to a lack of free calcium (as a result
of fat saponification) to appropriately bind the oxalate within
the bowel lumen. This leads to excessive free oxalate reabsorp-
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Table 1. Correlation Between IBD and CAD
Study

Patient population

Result

Dagli et al [5]

IBD: 40
Healthy patients: 40

IBD patients had a significant increase in carotid intimal
media thickness (cIMT) compared to the control group (P = 0.01)

Dorn et al [6]

CD: 4,532
UC: 9,533

SMR = 0.7 - 1.5 (NS)
SMR = 0.5 - 1.1 (NS)

Kristensen et al [7]

CD: 4,732
UC: 13,622

Relative risk of myocardial infarction = 1.49 (CI: 1.16 - 1.93) in patients
with an active flare and 2.05 (CI: 1.58 - 2.65) in chronic disease state

Yarur et al [8]

CD: 173
UC: 183

Adjusted hazard ratio for developing CAD in IBD
group = 4.08 (95% CI: 2.49 - 6.70)

Papa et al [9]

IBD: 52
Healthy patients: 20

cIMT significantly higher in IBD patients (0.63 ± 0.15 mm)
compared with controls (0.53 ± 0.08 mm) (P = 0.008)

Ruisi et al (current study)

IBD: 300

SMR = 0.0 (NS) 99.7% of the study patients did not have any
reported CV events over the 2-year follow-up period

tion from the bowel, which then crystallizes, with serum and
urine calcium leading to renal calculi and an increased overall
calcium oxalate production. This pathway, in addition to a high
inflammatory state, may as well provide the milieu for coronary artery disease (CAD)/ACS [3, 4].
In this study of 300 IBD patients we theorized that the
chronic high inflammatory states of these patients would provide an accelerated mechanism for premature CAD and/or
ACS. We assessed the correlation, if any, between the presence
of documented IBD and CAD events [5, 6].

Methods
We queried our hospital database (North Shore University
Hospital) to find IBD patients admitted to the hospital from
January 1, 2007 to December 31, 2008. This query was completed using ICD coding to identify patients with a pre-existing
diagnosis of IBD and/or IBD diagnosed during that specific
admission. Patients with traditional CV disease risk factors
including hypertension, congestive heart failure (CHF), diabetes, age ≥ 65, hyperlipidemia, family history (defined by ATP
III guidelines), end-stage renal disease (ESRD), and greater
than five pack-year smoking history were excluded from the
study cohort. The charts of the remaining 300 patients with
confirmed diagnosed IBD with no other traditional CV risk
factors were then analyzed for the incidence of CV disease
events including ACS encompassing STEMI, NSTEMI, and
unstable angina, positive stress testing, and any cardiac intervention that included coronary angioplasty and/or intracoronary stent implantation over the 2-year follow-up period.

Results
Basic demographic data were not obtained for this patient cohort other than that applied in the methods section since selection was performed via ICD coding only. Of the 300 patients
included, only one patient had a CV disease event. This patient
had a positive exercise stress thallium test. This one patient
258

demonstrated a reversible perfusion defect on myocardial perfusion imaging that was consistent with ischemia. Otherwise,
the remaining 299 patients (99.7%) did not have any reported
CV disease events over the 2-year follow-up period. Table 1
[5-9] lists previous similar studies that have investigated the
correlation between IBD and CAD. These studies demonstrated variable and conflicting results. In essence, the standard
mortality ratios have not shown an increase in CV mortality
in patients with IBD, but other studies have shown an increase
in intimal carotid thickness compared to a cohort of non-IBD
patients. Intimal carotid thickness has proved to be a marker
and reliable surrogate for the existence of clinically significant
CAD.

Discussion
The inflammatory state of ACS has been well validated in
both animal and human models. In addition, the pathophysiological milieu of atherosclerosis itself is a pro-inflammatory
state, with monocyte infiltration being one of the precursors of
fatty plaque development and eventual rupture. The presence
and oxidation of intimal lipid particles leads to an increase in
the expression of intimal adhesion molecules, which then facilitate the attachment of monocytes and other inflammatory
cells to the endothelium. In addition there is an increase in the
production of selectins that further provide anchoring and support of inflammatory cells to the endothelial integrins. Crohn’s
disease and ulcerative colitis are both systemic chronic diseases that create disturbances in bowel physiology. The central
process in IBD and the associated manifestations are the result
of B-cell production of IgG autoantibodies directed against
self-antigens in various organ systems such as the bowel, skin,
joints/synovium, eye, and coronary endothelium. The exact
etiology of IBD remains unclear. Multiple theories have been
postulated that include virus mediated autoimmune response,
dysbiosis or an imbalance in the gut microbiome or diet related such as a hypersensitivity to cow’s milk antigens, or even
bacterial infection related with some variable evidence linking
mycobacterium paratuberculosis and paramyxovirus to IBD

Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press Inc™ | www.jocmr.org

Ruisi et al

J Clin Med Res. 2015;7(4):257-261

[10, 11].
Regardless of the etiology the overall pathophysiological
effect of systemic inflammation is paramount to understanding
the disease manifestations of IBD. IBD patients traditionally
have elevated homocysteine, hs-CRP, and ESR levels. These
markers of systemic inflammation have been demonstrated
to have an association with CV disease. This level of inflammation correlates with enhanced endothelial adhesion of inflammatory cells in response to oxidation of intimal lipid particles. With this understanding one would then postulate that
IBD patients would be at higher risk for premature CAD and
CV events. The JUPITER trial demonstrated that relatively
healthy patients with LDL levels less than 130 but with elevated hs-CRP levels ≥ 2 mg/L had a significant reduction in
major adverse CV disease events including death when treated
with rosuvastatin. This landmark trial highlighted the potential
contribution of inflammation and the treatment of these processes via the pleotropic capability of statins to reduce major
CV events including death.
Review of the association between other chronic inflammatory diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), for example, also reveals
a potential association between chronic inflammation and an
increased risk of CAD events. In a sub-study analysis of RA
patients enrolled in the Nurses’ Health Study, Solomon et al
reported an increased incidence of myocardial infarction (MI)
but not stroke in patients with RA (adjusted relative risk of
MI 2.0 (95% confidence interval (CI): 1.23 - 3.29)) [10]. The
increased incidence of CV disease events in RA patients independent of traditional CV disease risk factors has been confirmed by several other smaller studies [11, 12]. Other studies have shown a statistically higher incidence of CV disease
events in patients with SLE as well, even after adjustment for
traditional CV risk factors [13].
The association between IBD and CV disease, however,
has proven more elusive. Despite the now accepted correlation
between IBD disease activity and the incidence of thromboembolic disease, there are currently conflicting data as to the
precise relationship, if any, between these IBD and CVD [14,
15]. A recently published Danish registry study with approximately 20,000 patients revealed an statistically significant increased risk of CV disease events in patients with active IBD
flares defined by prescription of pharmacologic therapy (such
as corticosteroids or anti-tumor necrosis factor agents). During such periods, the relative risk of MI was 1.49 (CI: 1.16 1.93) in patients with an active flare and 2.05 (CI: 1.58 - 2.65)
for persistent IBD activity. The relative risk of stroke and CV
death were similarly increased while the rates of such events
during remission periods were essentially commensurate with
the control group [7]. This retrospective analysis, however,
failed to incorporate smoking and obesity as CVD risk factors.
Similarly, a population-based cohort study in Taiwan demonstrated an increased risk of ACS events in patients with reported symptoms consistent with IBD. In this 13-year study,
patients with IBD had a 1.53 hazard ratio of ACS after adjustment for traditional CV disease risk factors. Furthermore, the
study also had two other important conclusions, namely, that
the incidence of ACS events correlated with the severity of
IBD symptoms and that the risk of ACS events was highest in

younger patients as well as women, findings that were demonstrated in a meta-analysis performed in the United States [1].
A retrospective longitudinal cohort study with matched controls by Yarur et al showed that IBD patients tended to have a
lower incidence of traditional CV disease risk factors but even
after adjustment, the hazard ratio for the development of CAD
events in the IBD group was 4.08 (95% CI: 2.49 - 6.70), further implying that IBD is an independent contributor to the
development of CAD [8].
While such retrospective/registry analyses imply an association, there is a fair amount of contrarian data as well. A biochemical analysis of patients with diagnosed Crohn’s disease
using the presence of arterial stiffness and increased levels of
lipoprotein-associated phospholipase A2 (Lp-PLA2) as surrogates for the risk of CVD events failed to show an association between IBD and CVD. In this study, patients with IBD
actually had lower levels of Lp-PLA2 and there was no statistically significant difference in arterial stiffness as assessed
by pulse wave velocity between IBD patients and controls.
Crohn’s patients had higher relative arterial stiffness, but this
was likely the result of the higher incidence of smoking in this
cohort [16]. This result conflicted with a previously published
assessment of 32 IBD patients in which IBD was associated
with a higher degree of arterial stiffness, although information
regarding history of disease burden and smoking history was
not included in the analysis [17]. Such conflicting data make
arrival at a definitive conclusion regarding IBD and CVD troublesome, as do the observational studies analyzing this association. The largest international meta-analysis on this topic by
Fumery et al included more than 200,000 IBD patients culled
from 33 studies. This study demonstrated no statistically significant association between IBD and CV mortality [18].
Other observational studies analyzing CVD surrogates
provide even further confounding results. Carotid intimal
thickness (CIMT) has proven to be a reliable surrogate for
the existence of CAD. Small studies have demonstrated an increase in intimal carotid thickness in IBD patients compared
to a cohort of non-IBD patients. In 2005 a small prospective
study by Papa et al demonstrated significantly higher values
of common carotid artery intimal-media thickness (IMT) in
IBD patients compared to a control group. This was suggestive that IBD patients may have an increase risk of early atherosclerosis than healthy controls [9]. In a follow-up study to
this, Maharshak et al compared measured IMT values between
61 IBD patients and 61 matched control patients. This study
found no significant difference in IMT between the two groups
and suggests that IBD is not a risk factor for accelerated atherosclerosis [19]. TNF alpha is an additional surrogate marker
relating IBD and early atherosclerosis. TNF alpha is cytokine
involved in both systemic inflammations and stimulates the
acute phase reaction. It is also well known that TNF alpha
is crucially involved in the pathogenesis and progression of
atherosclerosis. In the vasculature it has significant effects on
endothelial and vascular smooth muscle function. A common
pharmacologic target in IBD patients is the inhibition of TNF
alpha. However there is a paucity of literature on the effects of
TNF alpha inhibitors and CV disease in IBD patients. A recent
Danish nationwide cohort study in 2013 looked at IBD patient
and the incidence of CV events in relation to IBD flares. This
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study found that IBD patients were at an increase risk of CV
events during periods of active disease. The use of TNF alpha
inhibitors was one of the markers used to define periods of active disease/flares [20].
Our study is one of the few to directly look for the association of CV disease events (STEMI, NSTEMI, unstable
angina, along with ischemia on stress myocardial perfusion
testing, and any cardiac intervention that included coronary
angioplasty and/or intracoronary stent implantation) in a cohort of patients without any traditional thought of CV disease
risk factors other than IBD.
Our study did not demonstrate an association with IBD
and premature CV disease events in a 300 IBD patient cohort.
This result adds to the general conglomeration of studies implying that the association between chronic inflammation and
CV disease events may not be as simple as has been hypothesized. Simply stated, premature CV disease events were not
demonstrated in a cohort of IBD patients without traditional
CV disease risk factors. It is likely that the systemic inflammatory state alone is not sufficient to generate CV disease
events but rather that the chronic inflammation wrought by
IBD plays a role in facilitating an already present underlying
process such as the intimal lipid particle oxidation in hyperlipidemic patients which is known to be the necessary catalyst
for endothelial adhesion molecule production. This then leads
to inflammatory cell attachment to the endothelium and the
genesis of CAD [20]. What is clear is that more randomized
control trials assessing the interplay between these two processes are necessary, and whether active effective therapy to
suppress inflammation in these patients could alter the natural
progression of CV disease. Such studies must include rigorous
patient stratification based upon disease entity and, in particular, disease burden, degree of inflammation, and the mode of
treatment employed.
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